The Cost-Effectiveness of EndoPredict to Inform Adjuvant Chemotherapy Decisions in Early Breast Cancer
ConclusionWhile EndoPredict was found to be more expensive overall, its ability to affect a more optimal allocation of chemotherapy, resulted in long term health gains, however, they were insufficient to justify the high cost of EndoPredict.
Source: Health Policy and Technology - Category: Health Management Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Genetics | Health Management | Study